Microbix Biosystems Inc. T.MBX

YouTube Interview

[Method]

This has been posted before and is from about a month ago but is worth a watch,

I think it's around the 42nd minute where he describes the income statement. If he's right on exit revenue at $36m with $18m in margin less about $7.5m in interest and cash expenses leaves about $10m in free cash flow. 

It's kind of surprising it's only been watched 140 times. Maybe this BNN interview has people take a look. 

https://youtu.be/Jb7QIPGbeY0

[mercedesman]

Thx.  picking up where you left off.... if a $10M EBITDA , using a conservative multiple for a profitable Biotech of just 10X ... ...that's a $100M market cap ( vs today's .. $47M  suggesting a share price of close to $1 After not insignificant insider buys this months, that was enough for me.  I'm in for the 2 to 3 bagger.  the growth in revenue and

[lscfa]

$10 million ebitda x 10 / 161 million  = $0.62 /sh. That's why I said the analyst target of $1.40 is nuts.     Jun 20   Share 108,772,705   Warrants 23,284,552 Avg $0.36

[mjh9413]

Few of points to add. Doubt if one can apply a 10x multiple to this company. Presume the 50c+ options (3,8MM) have probably expired  The Conv Deb holders are the ongoing winners when it comes to an stakeholders benefitting..They have been in from about 2008 on and the current 23c conv price was down from original 65c and 90c (and int rates increased) because a credit facility with TD needed

[Method]

The multiple is on the cash flow. Just adjust the share count for the dilution and don't forget to add the interest back to the cash flow.  As for the "pumping" accusation. Presumably any of us long the stock, think it's cheap and appreciate Eden for shining a light on the story. I'm not sure why you want to besmirch the man's character for repeating what the CEO

[Method]

That number included interest expense so it's closer to $10m free cash flow vs EBITDA. Plus there is opportunities for growth in the revenue number of which almost half will fall to free cash flow.    Also they have the potential partnership announcement on Kinlytic® urokinase for which there is no associated revenue and cash flow yet.